
Stock News•3 weeks ago
Beyond Cellular Models: Longevica Capitalizes on World's Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline
Longevica formed a scientific advisory board to convert its $13M, 16,000-subject in vivo longevity study into AI-driven drug discovery, pet health, and human therapies. The move aims to unlock a human...














